Open AccessTrial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus
Author(s) -
Kenji Kabashima,
Takayo Matsumura,
Hiroshi Komazaki,
Makoto Kawashima
Publication year - 2020
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1917006
Subject(s) - medicine , atopic dermatitis , dermatology , dupilumab , monoclonal , monoclonal antibody , immunology , antibody
Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in atopic dermatitis. In phase 2 studies, nemolizumab lessened the severity of atopic dermatitis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom